229 related articles for article (PubMed ID: 21138955)
1. Directed therapy of subtypes of triple-negative breast cancer.
Carey LA
Oncologist; 2010; 15 Suppl 5():49-56. PubMed ID: 21138955
[TBL] [Abstract][Full Text] [Related]
2. Directed therapy of subtypes of triple-negative breast cancer.
Carey LA
Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
[TBL] [Abstract][Full Text] [Related]
3. Molecular stratification of triple-negative breast cancers.
Perou CM
Oncologist; 2010; 15 Suppl 5():39-48. PubMed ID: 21138954
[TBL] [Abstract][Full Text] [Related]
4. Molecular stratification of triple-negative breast cancers.
Perou CM
Oncologist; 2011; 16 Suppl 1():61-70. PubMed ID: 21278442
[TBL] [Abstract][Full Text] [Related]
5. Updates in the treatment of basal/triple-negative breast cancer.
Shastry M; Yardley DA
Curr Opin Obstet Gynecol; 2013 Feb; 25(1):40-8. PubMed ID: 23222093
[TBL] [Abstract][Full Text] [Related]
6. Triple negative breast cancer: a brief review of its characteristics and treatment options.
Griffiths CL; Olin JL
J Pharm Pract; 2012 Jun; 25(3):319-23. PubMed ID: 22551559
[TBL] [Abstract][Full Text] [Related]
7. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
Kurebayashi J
Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials in triple negative breast cancer.
Reeder-Hayes KE; Carey LA; Sikov WM
Breast Dis; 2010; 32(1-2):123-36. PubMed ID: 21778571
[TBL] [Abstract][Full Text] [Related]
9. Management of triple negative breast cancer.
Oakman C; Viale G; Di Leo A
Breast; 2010 Oct; 19(5):312-21. PubMed ID: 20382530
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?
Burness ML; Grushko TA; Olopade OI
Cancer J; 2010; 16(1):23-32. PubMed ID: 20164687
[TBL] [Abstract][Full Text] [Related]
11. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
Nanda R
Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
13. Current treatment options in triple negative breast cancer.
Rodler E; Korde L; Gralow J
Breast Dis; 2010; 32(1-2):99-122. PubMed ID: 21778572
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
Damasceno M
Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
[TBL] [Abstract][Full Text] [Related]
15. Metastatic triple-negative breast cancer.
Rakha EA; Chan S
Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
[TBL] [Abstract][Full Text] [Related]
16. [Current status and future perspectives for the treatment of triple-negative breast cancer in Japan].
Masuda N; Yasojima H; Mizutani M; Yamamura J
Gan To Kagaku Ryoho; 2012 Apr; 39(4):512-8. PubMed ID: 22504674
[TBL] [Abstract][Full Text] [Related]
17. Targeting triple negative breast cancer: is p53 the answer?
Turner N; Moretti E; Siclari O; Migliaccio I; Santarpia L; D'Incalci M; Piccolo S; Veronesi A; Zambelli A; Del Sal G; Di Leo A
Cancer Treat Rev; 2013 Aug; 39(5):541-50. PubMed ID: 23321033
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
von Minckwitz G; Müller BM; Loibl S; Budczies J; Hanusch C; Darb-Esfahani S; Hilfrich J; Weiss E; Huober J; Blohmer JU; du Bois A; Zahm DM; Khandan F; Hoffmann G; Gerber B; Eidtmann H; Fend F; Dietel M; Mehta K; Denkert C
J Clin Oncol; 2011 Jun; 29(16):2150-7. PubMed ID: 21519019
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer: role of antiangiogenic agents.
Greenberg S; Rugo HS
Cancer J; 2010; 16(1):33-8. PubMed ID: 20164688
[TBL] [Abstract][Full Text] [Related]
20. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
